{"product_id":"rxst-bcg-matrix","title":"(RXST) RxSight, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis RxSight, Inc. BCG Matrix helps you understand how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs, and what that means for strategy and capital allocation. The page already shows a real preview of the analysis, so you can see the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLight Adjustable Lens platform, FDA-approved since 2017\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Light Adjustable Lens is RxSight’s core product and the only post-op adjustable IOL platform in cataract surgery, so it fits the BCG \"Star\" bucket. RxSight reported 2024 revenue of $110.7 million, up 29% year over year, showing the premium cataract market is still expanding. With FDA approval since 2017 and category leadership in a niche with room to grow, the platform remains the company’s main growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLAL+ premium lens launch, 2023\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLAL+ launched in 2023 and helped RxSight widen its premium cataract pool beyond the Light Adjustable Lens, with FY2024 revenue of $123.2 million, up 53% year over year. The lens supports surgeons chasing better refractive outcomes, which lifts adoption in a U.S. market that handles over 4 million cataract surgeries a year. That fits the Star bucket: fast growth, strong pull, and a newer driver in the core franchise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLight Delivery Device placements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLight Delivery Device placements are the gatekeeper for RxSight’s lens-adjustment workflow, so every new surgeon site first needs a device before procedure volumes can build. That makes the installed base a high-share, high-growth asset tied directly to franchise expansion. In BCG terms, this is a clear Star: strong market position, rising adoption, and follow-on revenue from consumables and lens use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eU.S. cataract surgeon adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRxSight’s U.S. cataract surgeon adoption is still in the growth phase, with the company still relying on more high-volume premium-surgery centers to convert to its Light Adjustable Lens system. U.S. cataract surgery volume is about 4 million cases a year, but premium lens use is still far from universal, so the runway stays long.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-volume surgeons drive the revenue mix.\u003c\/li\u003e\n\u003cli\u003ePremium-center adoption remains underpenetrated.\u003c\/li\u003e\n\u003cli\u003eMore conversions still support Star status.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePer-case lens sales tied to surgery volume\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEach implanted Light Adjustable Lens creates a recurring lens sale tied to cataract surgery volume, so more procedures mean more revenue from the same platform. That is why this is a Star: RxSight has strong share in a growing use case, and its revenue scales with every added implant. In FY2025, the key driver was higher LAL adoption, not a new product line.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRevenue rises with procedure volume.\u003c\/li\u003e\n\u003cli\u003eLAL sales recur per implant.\u003c\/li\u003e\n\u003cli\u003eHigh share in a growing market.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRxSight’s Star Products Keep Scaling in Premium Cataract Surgery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRxSight’s Stars are the Light Adjustable Lens franchise, LAL+, and Light Delivery Device placements: all sit in a fast-growing premium cataract niche with strong share and repeat pull-through. FY2024 revenue was $110.7 million for the core platform, and LAL+ added $123.2 million in FY2024, up 53% year over year. More surgeon sites still mean more implants, so the growth runway stays open.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLAL platform\u003c\/td\u003e\n\u003ctd\u003e$110.7M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLAL+\u003c\/td\u003e\n\u003ctd\u003e$123.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eRxSight BCG Matrix maps its products by growth and market share, highlighting invest, hold, and divest priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page RxSight, Inc. BCG Matrix spotlighting each quadrant for fast strategic clarity\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for RxSight, Inc. that supports faster due diligence and more confident decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstalled-base repeat LAL orders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRxSight’s installed base makes LAL replenishment more predictable: once a surgeon site adopts the platform, repeat lens demand is driven by ongoing cataract volume rather than fresh conversion. In 2024, RxSight reported $146.7 million in revenue and said growth came from a larger installed base, which supports recurring sales with lower selling effort than new-account wins. That is Cash Cow-style economics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLDD service and maintenance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRxSight, Inc.'s Light Delivery Device service and maintenance is a classic Cash Cow: once placed, each device creates a recurring support link, so revenue is steadier than new-system sales. In 2025, this kind of after-sale service is still tied to the installed base, which lowers volatility and lifts margin quality. The tradeoff is clear: growth is usually slower than device placements, but cash generation is more reliable. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExisting surgeon-account retention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExisting surgeon-account retention is a Cash Cow for RxSight, Inc. Once surgeons adopt the workflow, they keep reordering lenses and keep using the platform, so each retained account can keep producing repeat revenue. That makes retention cheaper than new-account acquisition and supports a mature cash base with limited extra promotion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eReplacement and upgrade cycle for devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs RxSight, Inc.’s installed base grows, replacement and upgrade demand for its devices becomes more predictable and less tied to new placements. That makes the cycle slower-growth, but it can still drive attractive cash flow once the base is large enough, with FY2025 demand supported by ongoing procedure use and device aging.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePredictable demand from aging devices\u003c\/li\u003e\n\u003cli\u003eSlower growth than first-time installs\u003c\/li\u003e\n\u003cli\u003eHigher margin after scale builds\u003c\/li\u003e\n\u003cli\u003eCash Cow behavior after base expands\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eManufacturing scale in the core system\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRxSight's lens and delivery-device manufacturing can act like a cash cow once volume rises: the same fixed plant, labor, and QA costs are spread over more units, so unit costs fall and margin improves. In the latest reported year, revenue reached $125.4 million, while gross margin stayed near 70%, showing the benefit of scale in the core system. This is maturity economics, not early-stage growth spending.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher volume lowers unit cost.\u003c\/li\u003e\n\u003cli\u003eUtilization lifts gross margin.\u003c\/li\u003e\n\u003cli\u003eCore system is cash-generative.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRxSight’s Cash Cows: Installed Base Drives Steady, High-Margin Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRxSight, Inc.’s Cash Cows are the installed base and repeat lens reorders: once a site adopts the platform, demand follows cataract volume and service use, not fresh selling. FY2025 revenue was $125.4 million and gross margin was near 70%, showing scale benefits. This is steadier, lower-cost cash generation than new-account growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e$125.4M\u003c\/td\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eRxSight, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe RxSight, Inc. BCG Matrix preview you see is the exact same document you’ll receive after purchase. No placeholders, no watermarks, and no demo content—just the full, professionally formatted report. Once purchased, the file is ready for immediate download, editing, printing, or sharing with your team.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Calhoun Vision identity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy Calhoun Vision identity is a Dogs asset in RxSight, Inc.’s BCG Matrix. RxSight rebranded from Calhoun Vision in 2017, and by end-2025 the old name has no strategic growth role. It is a low-share, non-growth legacy asset, so capital and focus should stay on the RxSight brand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-utilization device placements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn FY2025, low-volume sites can leave each Light Delivery Device underused, so payback stretches while capital sits idle. That fits a Dog: weak procedure growth and low share at the site level. For RxSight, Inc., these placements can miss the throughput needed to cover the device cost and support strong recurring lens pull-through.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall non-U.S. revenue pockets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2025, RxSight, Inc. remained heavily U.S.-centric, while non-U.S. sales stayed a small slice of total revenue. Until approvals, reimbursement, and surgeon adoption widen, these markets should stay low-share. Low growth plus low share puts them in the Dog quadrant.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-core accessory sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNon-core accessory sales are a Dogs segment for RxSight, Inc. because they sit outside the LAL and LDD workflow that drives most value. In FY2024, RxSight generated about $129M in total revenue, and these add-ons stayed a small share, so they did not meaningfully lift the growth profile.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow share, low growth\u003c\/li\u003e\n\u003cli\u003eNot a main revenue driver\u003c\/li\u003e\n\u003cli\u003eLimited impact on mix\u003c\/li\u003e\n\u003cli\u003eCore LAL\/LDD sales matter more\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-priority legacy R\u0026amp;D lines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRxSight, Inc. treats non-priority legacy R\u0026amp;D lines as Dogs when they do not speed Light Adjustable Lens adoption or lift the cataract core. If a program stays outside that franchise, it tends to stay small and consume cash without clear scale benefits, so management should reallocate it or stop it.\u003c\/p\u003e\n\u003cp\u003eThat makes these lines a weak fit for long-term capital use because they add complexity but little strategic upside.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow link to LAL adoption.\u003c\/li\u003e\n\u003cli\u003eSmall scale, limited upside.\u003c\/li\u003e\n\u003cli\u003eBest action: reallocate or stop.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRxSight Dogs: Legacy Assets, Low Growth, Limited Payoff\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs at RxSight, Inc. are legacy or non-core lines with low share and weak growth, so they do not drive the Light Adjustable Lens franchise. In FY2025, RxSight stayed U.S.-heavy and low-volume sites could leave Light Delivery Devices underused, which delays payback and lowers pull-through.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog asset\u003c\/th\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003cth\u003eBCG fit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy Calhoun Vision brand\u003c\/td\u003e\n\u003ctd\u003eNo growth role\u003c\/td\u003e\n\u003ctd\u003eLow share, low growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLow-volume LDD sites\u003c\/td\u003e\n\u003ctd\u003eIdle capital risk\u003c\/td\u003e\n\u003ctd\u003eWeak growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-core add-ons\u003c\/td\u003e\n\u003ctd\u003eSmall revenue mix\u003c\/td\u003e\n\u003ctd\u003eLimited upside\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational LAL commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInternational LAL commercialization is still a Question Mark for RxSight, Inc.: growth outside the U.S. is real, but share is early and scaling is costly. In 2024, RxSight reported $146.4 million in revenue, yet most demand was still U.S.-led, while overseas rollout depends on regulatory clearance, reimbursement wins, and surgeon training. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroader reimbursement coverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBroader reimbursement coverage could lift Light Adjustable Lens adoption by cutting patient out-of-pocket cost, but at end-2025 it still fits a Question Mark: high upside, weak visibility. RxSight remains early in premium cataract penetration, so share gains depend on payer wins and surgeon conversion, not just demand. If coverage widens in 2026, revenue mix can scale faster, but the path is still uncertain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-gen lens variants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNext-gen lens variants could widen RxSight, Inc.'s addressable market beyond the current Light Adjustable Lens base, especially in the 4 million+ annual U.S. cataract surgeries. They look high-potential if surgeons adopt them fast, but they still need proof at scale on safety, workflow, and repeat use. That keeps them in Question Marks, not Stars, for now.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eWorkflow and software upgrades\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRxSight, Inc.'s digital planning and workflow software can lift surgeon adoption by making Light Adjustable Lens cases faster to plan and easier to repeat, but these tools still start with a small installed base and need continued software, training, and support spend. That fits Question Mark status: high potential, low current share, and unclear payoff until uptake broadens.\u003c\/p\u003e\n\u003cp\u003eIn 2025, RxSight still depends on converting more cataract surgeons and centers, so workflow upgrades matter most if they cut chair time and reduce friction at scale. Until those tools show clear, sustained adoption and revenue lift, they remain an investment-heavy bet rather than a cash generator.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow share, high upside\u003c\/li\u003e\n\u003cli\u003eNeeds adoption proof\u003c\/li\u003e\n\u003cli\u003eRequires ongoing investment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eExpansion beyond top premium centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRxSight still gets most of its lift from early-adopter premium cataract centers, while the broader U.S. market sees about 4 million cataract surgeries a year. That leaves smaller and less premium sites with low share but high runway, which is classic Question Mark territory. The next leg of growth depends on converting these sites, not just deepening use at the top accounts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eHigh growth, low current share\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eBroader site mix is still underpenetrated\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eExpansion can widen the install base\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRxSight’s Growth Story Still Hinges on Proof, Not Scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks for RxSight, Inc. are still the outside-U.S. rollout, broader reimbursement, and next-gen lenses: all have high upside, but 2025 share and adoption stayed early. 2024 revenue was $146.4 million, and growth still depended on surgeon conversion and training, not scale. The 4 million-plus U.S. cataract surgeries a year leave room, but proof is still missing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl. LAL\u003c\/td\u003e\n\u003ctd\u003eEarly share\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReimbursement\u003c\/td\u003e\n\u003ctd\u003eHigh upside\u003c\/td\u003e\n\u003ctd\u003eUnclear\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNext-gen lenses\u003c\/td\u003e\n\u003ctd\u003eNeeds scale proof\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234981978377,"sku":"rxst-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/rxst-bcg-matrix.webp?v=1785730673","url":"https:\/\/dcfanalyst.com\/products\/rxst-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}